Ischaemic heart disease accounts for nearly half of the global cardiovascular disease burden. Aetiologies relating to heart disease are complex, but dyslipidaemia, oxidative stress and inflammation are cardinal features. Despite preventative measures and advancements in treatment regimens with lipid-lowering agents, the high prevalence of heart disease and the residual risk of recurrent events continue to be a significant burden to the health sector and to the affected individuals and their families. The development of improved risk models for the early detection and prevention of cardiovascular events in addition to new therapeutic strategies to address this residual risk are required if we are to continue to make inroads into this most prevalent of diseases. Metabolomics and lipidomics are modern disciplines that characterize the metabolite and lipid complement respectively, of a given system. Their application to ischaemic heart disease has demonstrated utilities in population profiling, identification of multivariate biomarkers and in monitoring of therapeutic response, as well as in basic mechanistic studies. Although advances in magnetic resonance and mass spectrometry technologies have given rise to the fields of metabolomics and lipidomics, the plethora of data generated presents challenges requiring specific statistical and bioinformatics applications, together with appropriate study designs. Nonetheless, the predictive and re-classification capacity of individuals with various degrees of risk by the plasma lipidome has recently been demonstrated. In the present review, we summarize evidence derived exclusively by metabolomic and lipidomic studies in the context of ischaemic heart disease. We consider the potential role of plasma lipid profiling in assessing heart disease risk and therapeutic responses, and explore the potential mechanisms. Finally, we highlight where metabolomic studies together with complementary -omic disciplines may make further inroads into the understanding, detection and treatment of ischaemic heart disease.
Skip Nav Destination
Article navigation
Review Article|
November 12 2012
Metabolomics and ischaemic heart disease
Aliki A. Rasmiena;
Aliki A. Rasmiena
1Metabolomics Laboratory, Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne 3004, Australia
Search for other works by this author on:
Theodore W. Ng;
1Metabolomics Laboratory, Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne 3004, Australia
Correspondence: Dr Theodore W. Ng (email [email protected]).
Search for other works by this author on:
Peter J. Meikle
Peter J. Meikle
1Metabolomics Laboratory, Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne 3004, Australia
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
May 21 2012
Revision Received:
September 04 2012
Accepted:
September 17 2012
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2013 Biochemical Society
2013
Clin Sci (Lond) (2013) 124 (5): 289–306.
Article history
Received:
May 21 2012
Revision Received:
September 04 2012
Accepted:
September 17 2012
Citation
Aliki A. Rasmiena, Theodore W. Ng, Peter J. Meikle; Metabolomics and ischaemic heart disease. Clin Sci (Lond) 1 March 2013; 124 (5): 289–306. doi: https://doi.org/10.1042/CS20120268
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |